Prognostic significance of NF-κB in unresectable non-small cell carcinoma of the lung treated with concomittant chemoradiotherapy Eşzamanli kemoradyoterapi ile tedavi edilen evre III küçük hücreli dişi akciǧer kanserlerinde NF-κB'nin prognostik önemi

EROĞLU C., SOYUER I., SOYUER S., YILDIZ O. G., ORHAN O., GÜNDOĞ M., ...Daha Fazla

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.15, sa.3, ss.138-143, 2005 (Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 3
  • Basım Tarihi: 2005
  • Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.138-143
  • Anahtar Kelimeler: Chemoradiotherapy, NF-κB, NSCLC, Prognostic factor
  • Erciyes Üniversitesi Adresli: Evet

Özet

The aim of this study is to determine the prognostic value of transcription factor nucleer factor kappa B (NF-κB) in unresectable non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy. Twenty-eight unresectable NSCLC patients treated with concurrent chemoradiotherapy with paclitaxel + carboplatin were enrolled in this study. All patients received paclitaxel + carboplatin chemotherapy and radiotherapy concomittantly as primary treatment. Then patients received 0-4 cycles chemotherapy as a consolidation treatment. Immunohistochemistry was performed on paraffin embedded tissue. NF-κB monoclonal antibadies were used for the staining. The progression free survival and overall survival diference were analised between NF-κB positive and negative groups. For NF-κB a specimen was judged positive if more than 10% of the total cancer cells in a single field of view showed a response. In patients who NF-xB was stained more than 10%, the disease free survival was better although there was not statistically significant difference. But in two groups, the overall survival was the same. NF-κB may be a useful prognostic factor in unresectable NSCLC patients.